Latanoprost (Xalatan)

01/01/2016 - "BAK-free latanoprost appears to be effective in protecting ocular surface integrity in glaucoma patients but further studies are needed to confirm this beneficial effect."
02/01/2001 - "These effects of latanoprost may be beneficial in the management of glaucoma patients."
01/01/2021 - "This study evaluated whether a preservative-free latanoprost (PFL) is as effective as preservative-containing latanoprost (PCL) for reducing eye pressure and whether PFL is better tolerated in patients with glaucoma. "
03/01/2003 - "However, latanoprost was effective in only a minority of pediatric cases of glaucoma and is contraindicated in all forms of uveitic glaucoma. "
01/01/1996 - "Latanoprost has the potential for becoming a new first-line treatment for glaucoma."

07/01/2020 - "In this study, OMDI 0.002% demonstrated a clinically significant reduction in IOP and was well tolerated in patients with primary open-angle glaucoma and OHT who were non-/low responders to latanoprost."
12/01/2018 - "Therapeutic efficacy of latanoprost on primary open angle glaucoma: A protocol for a systematic review of randomized controlled trial."
09/01/2019 - "Materials and methods: New cases of primary open-angle glaucoma treated with topical latanoprost as first-line treatment were enrolled in this prospective study. "
12/01/2018 - "To determine the efficacy of locally produced Latanoprost in reducing the intraocular pressure (IOP) in patients with Primary open-angle glaucoma (POAG). "
12/01/2018 - "Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma."

07/01/2014 - "PF latanoprost was efficacious in reducing IOP in a randomized, investigator-masked, multinational trial in patients with POAG/ocular hypertension (n = 404). "
01/01/2007 - "The study suggests that patients with ocular hypertension already treated with latanoprost monotherapy will continue to have, on average, at least midterm stable pressures, low incidence of side effects and discontinuations, as well as "very good" to "excellent" physician ratings of efficacy, tolerability, and patient satisfaction."
01/01/2007 - "353 patients with ocular hypertension were included and treated with latanoprost monotherapy historically (1.4 +/- 1.3 years) and within the observational period of the study for a mean of 2.2 +/- 1.1 years. "
01/01/2007 - "A subanalysis of patients with ocular hypertension who were previously treated on latanoprost monotherapy and continued within the study on this same medication for at least 6 months. "
09/01/1993 - "In a randomized, double-masked, placebo-controlled study, PhXA41 (0.006%) was given topically twice daily for 1 week to one eye each of 22 volunteers with normotension or ocular hypertension. "

02/01/2005 - "The aim of this study was to evaluate the efficacy of 0.005% latanoprost in lowering intraocular pressure (IOP) in patients with chronic angle-closure glaucoma (CACG) and no visible ciliary-body face. "
02/01/2005 - "Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: a preliminary study."
08/01/2002 - "Two independent, prospective trials were recently conducted to assess the efficacy of latanoprost in reducing intraocular pressure (IOP) in patients with primary angle-closure glaucoma (PACG). "
03/01/2016 - "To systematically evaluate the safety and efficacy of latanoprost monotherapy for the treatment of patients with angle-closure glaucoma. "
01/01/2009 - "Efficacy of latanoprost in management of chronic angle closure glaucoma."

03/01/2003 - "NTG: Latanoprost is effective in normal tension glaucoma (NTG), lowering IOP, improving pulsatile ocular blood flow and increasing ocular perfusion pressure. "
12/01/2005 - "To evaluate the intraocular pressure (IOP)-lowering efficacy of latanoprost in normal-tension glaucoma (NTG). "
09/01/2003 - "To study the effect of instillation of latanoprost on the diurnal variation in the intraocular pressure(IOP), blood pressure, and pulse rate in patients with normal-tension glaucoma(NTG). "
02/01/1997 - "Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment."
12/01/2021 - "Patient 2 was a 29-year-old man with a normal-tension glaucoma (NTG) diagnosis for 7 years in the right eye treated with latanoprost. "